Patient-specific melanoma-associated antigens presented by autologous dendritic cells (DC-Mel-Ag)

Patient-specific melanoma-associated antigens presented by autologous dendritic cells represent a personalized therapeutic target complex used in cancer immunotherapy. This approach involves harvesting a patient's own dendritic cells and loading them with antigens derived from the patient's specific melanoma tumor, such as neoantigens or shared tumor-associated antigens like MAGE-A3 and MART-1 (Source: National Cancer Institute). The primary biological function of this complex is to serve as a potent stimulus for the adaptive immune system, specifically activating CD8+ cytotoxic T-lymphocytes and CD4+ helper T-cells (Source: PubMed, PMID: 31209119). By presenting these antigens in the context of major histocompatibility complex (MHC) molecules, the dendritic cells effectively prime the immune system to recognize and attack malignant cells expressing those specific markers. In the context of disease, this target is utilized to treat advanced melanoma, aiming to overcome the tumor's ability to evade immune detection (Source: Journal of Clinical Oncology). Drugs or vaccines interacting with this target are typically autologous cell therapies, such as TLPLDC, which are often administered in combination with checkpoint inhibitors like pembrolizumab to enhance efficacy (Source: ClinicalTrials.gov). The therapeutic goal is to establish long-term immunological memory against the cancer, potentially preventing recurrence and improving overall survival.

Other names

Autologous dendritic cell-based melanoma vaccineNeoantigen-loaded dendritic cellsPatient-specific tumor-associated antigensDC-based immunotherapy for melanomaAutologous antigen-presenting cells

Induction of a specific T-cell mediated immune response by presenting tumor-specific or tumor-associated antigens via MHC class I and II molecules on the surface of autologous dendritic cells to naive and memory T-cells (Source: PubMed, PMID: 31209119).